Ambrx Biopharma Inc. (AMAM) concluded trading on Thursady at a closing price of $27.93, with 7.75 million shares of worth about $216.32 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 107.81% during that period and on Thursady the price saw a gain of about 0.83%. Currently the company’s common shares owned by public are about 63.29M shares, out of which, 55.08M shares are available for trading.
Stock saw a price change of 0.58% in past 5 days and over the past one month there was a price change of 0.68%. Year-to-date (YTD), AMAM shares are showing a performance of 96.14% which increased to 513.85% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.64 but also hit the highest price of $28.15 during that period. The average intraday trading volume for Ambrx Biopharma Inc. shares is 1.75 million. The stock is currently trading 0.59% above its 20-day simple moving average (SMA20), while that difference is up 24.20% for SMA50 and it goes to 83.65% higher than SMA200.
Ambrx Biopharma Inc. (NASDAQ: AMAM) currently have 63.29M outstanding shares and institutions hold larger chunk of about 92.16% of that.
The stock has a current market capitalization of $1.77B and its 3Y-monthly beta is at -1.93. It has posted earnings per share of -$2.02 in the same period. It has Quick Ratio of 13.28 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AMAM, volatility over the week remained 0.49% while standing at 0.33% over the month.
Analysts are in expectations that Ambrx Biopharma Inc. (AMAM) stock would likely to be making an EPS of -$0.39 in the current quarter, while forecast for next quarter EPS is -$0.4 and it is -$1.61 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.45 which is -$0.34 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to drop by -375.86% while it is estimated to decrease by -16.49% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JMP Securities on September 25, 2023 offering a Mkt outperform rating for the stock and assigned a target price of $15 to it. Coverage by BTIG Research stated Ambrx Biopharma Inc. (AMAM) stock as a Buy in their note to investors on September 12, 2023, suggesting a price target of $26 for the stock. On July 31, 2023, RBC Capital Mkts Initiated their recommendations, while on June 14, 2023, B. Riley Securities Initiated their ratings for the stock with a price target of $26. Stock get an Outperform rating from Oppenheimer on June 02, 2023.
